Loading...
•
Mar 31, 2020
Guardant Health Q1 2020 Earnings Report
Revenue increased significantly, driven by precision oncology testing, but the company withdrew its 2020 financial guidance due to the COVID-19 pandemic.
Key Takeaways
Guardant Health reported an 84% increase in revenue for Q1 2020 compared to the prior year period, driven by growth in precision oncology testing. However, due to the uncertainty caused by the COVID-19 pandemic, the company withdrew its previously announced annual revenue and net loss guidance for 2020.
Revenue of $67.5 million, an 84% increase over Q1 2019.
Clinical tests reported were 15,257, a 60% increase over Q1 2019.
Biopharmaceutical tests reported were 5,266, a 40% increase over Q1 2019.
The company onboarded over 100 clinical sites for the ECLIPSE trial.
Guardant Health
Guardant Health
Guardant Health Revenue by Segment
Revenue by Segment
Oncology Revenue
CapyFin.com Forward Guidance
Due to the uncertainty caused by the COVID-19 pandemic, Guardant Health is withdrawing its previously announced annual revenue and net loss guidance for 2020.